

ASX RELEASE

11 August 2014

**Novogen to Summarise Clinical Strategies
and Capital-Raising Programs at General Meeting**

11 August 2014, SYDNEY: The pioneering research and development strategies that underpin the efforts of Novogen Ltd (ASX: NRT) to create world-first medicines for the treatment of cancer and degenerative diseases will be unveiled as part of the Company's General Meeting of Shareholders on Wednesday, 13 August 2014.

At the General Meeting, shareholders will vote on two resolutions to allow the Company to issue new shares and raise additional working capital to continue the Company's expanding R&D programs and to underwrite its progression into a clinical-stage company.

The General Meeting will commence at 2.00 p.m. Immediately following that, the Company will host an Open Briefing to review strategies for R&D, clinical trials and company growth. The briefing is open to the general public and will be held 2.30 – 5.00 p.m.

The following Novogen executives and topics are scheduled:

Graham Kelly, PhD
Executive Chairman & CEO, Novogen
"The Novogen Opportunity... Cancer and Well Beyond"

David Brown, PhD
Group Chief Scientific Officer, Novogen
"The Unique Multiple Personality Complex of Super-Benzopyrans Driving the Novogen Strategy"

Graham Kelly, PhD
Executive Chairman & CEO, Novogen
"CanTx, Cantrixil and Abdominal Cancers"

Eleanor Ager, PhD
Glioblastoma Program Manager, Novogen
"Is Trilexium Capable of Breaking Barriers for the Successful Treatment of Brain and Neural Cancers?"

Stephen Palmer, PhD
Degenerative Disease Program Director, Novogen
"Potential Treatments for Alzheimer's, Muscular Dystrophies and Stroke Injury Among the Super-Benzopyrans"

Peter Gunning, PhD
Assistant Dean (Research), University of New South Wales School of Medicine;
Non-Executive Director, Novogen
"Tropomyosins: An Important New Clinical Target Heralding the Dawn of a New Range of Drugs for Unmet Clinical Needs"

NOVOGEN LIMITED
(ASX: NRT)



Justine Stehn, PhD
Anti-Tropomyosin Program Director, Novogen
“The Novogen ATM Oncology Drug Program”

Graham Kelly, PhD
Executive Chairman & CEO, Novogen
“Summary, Growth and the Future”

Both the General Meeting of Shareholders and the Open Briefing will be held at the offices of Computershare Investor Services Pty Ltd located at Level 4, 60 Carrington Street, Sydney.

About Novogen Limited

Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Company has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to have a uniform cytotoxic effect against both cancer stem cell and regular daughter cancer cells and are being developed in the first instance for the treatment of ovarian cancer, neural cancers (glioblastoma, neuroblastoma) and prostate cancer. ATM compounds target the cancer cell cytoskeleton and are being developed in combination with other anti-cytoskeleton drugs to deliver comprehensive destruction of the cancer cell cytoskeleton in cancers such as melanoma, neural cancers and prostate cancer.

Further information is available on the Company's website, www.novogen.com.

For Further Information Contact:

Jay Pleass

Ethical Strategies
+61 (0) 2 8904 7320
+61 (0) 412 623 578

Dr. Graham Kelly

Executive Chairman & CEO
Novogen Group
Graham.Kelly@novogen.com
+61 (0) 2 9472 4100